Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately‐to‐Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U‐ACHIEVE: 215. (October 2019)